ASH: Roche's antibody-drug conjugate Polivy added to chemo-antibody combo boosts survival in early-stage lymphoma

Breakthroughs in drug development have begun to unlock the potential of antibody-drug conjugates, therapies designed to better target proteins on tumor cells. Genentech’s Polivy has become an early winner in blood cancer, and now the drugmaker is revealing promising results in getting into patients even sooner.